Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.

ABSTRACT: Sclerostin antibody (Scl-Ab) is an anabolic bone agent that has been shown to increase bone mass in clinical trials of adult diseases of low bone mass, such as osteoporosis and osteogenesis imperfecta (OI). Its use to decrease bone fragility in pediatric OI has shown efficacy in several growing mouse models, suggesting translational potential to pediatric disorders of low bone mass. However, the effects of pharmacologic inhibition of sclerostin during periods of rapid growth and development have not yet been described with respect to the cranium, where lifelong deficiency of functioning sclerostin leads to patterns of excessive bone growth, cranial compression, and facial palsy. In the present study, we undertook dimensional and volumetric measurements in the skulls of growing Brtl/+ OI mi

SUBMITTER: Scheiber AL 

PROVIDER: S-EPMC7458133 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature